Leveraging DNA methylation to create Epigenetic Biomarker Proxies that inform clinical care: A new framework for Precision Medicine
2024

Using DNA Methylation to Create Biomarkers for Clinical Care

Sample size: 30430 publication 10 minutes Evidence: high

Author Information

Author(s): Carreras-Gallo Natàlia, Chen Qingwen, Balagué-Dobón Laura, Aparicio Andrea, Giosan Ilinca M., Dargham Rita, Phelps Daniel, Guo Tao, Mendez Kevin M., Chen Yulu, Carangan Athena, Vempaty Srikar, Hassouneh Sayf, McGeachie Michael, Mendez Tavis, Comite Florence, Suhre Karsten, Smith Ryan, Dwaraka Varun B., Lasky-Su Jessica A.

Primary Institution: Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School

Hypothesis

Can DNA methylation algorithms serve as effective proxies for clinical biomarkers in predicting chronic diseases and mortality?

Conclusion

The study demonstrates that epigenetic biomarker proxies (EBPs) can effectively predict chronic diseases and mortality, often outperforming traditional clinical biomarkers.

Supporting Evidence

  • EBPs showed significant associations with 12 chronic diseases and mortality.
  • 62% of EBPs had higher hazard ratios for disease outcomes compared to observed biomarkers.
  • EBPs demonstrated high sensitivity and specificity in detecting deviations from normal clinical ranges.
  • Longitudinal tracking of EBPs correlated well with observed clinical values.

Takeaway

Scientists created new tools that use DNA information to help doctors understand health better and predict diseases without needing expensive tests.

Methodology

The study developed epigenetic biomarker proxies (EBPs) using DNA methylation data from over 30,000 individuals, assessing their associations with chronic diseases and mortality.

Potential Biases

Self-selection bias may exist as participants were primarily healthier individuals seeking preventative care.

Limitations

The study's findings may be limited by the potential for overfitting in the models and the need for further validation across diverse populations.

Participant Demographics

Participants included over 30,000 individuals from two cohorts, with a focus on diverse health statuses.

Statistical Information

P-Value

5.8e-04

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1101/2024.12.06.24318612

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication